Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug

Investopedia12-20 21:03

Key Takeaways Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial.The new drug, CagriSema, led patients to lose 22.7% of their ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492647445?lang=en_US&edition=fundamental","thumbnail":"https://www.investopedia.com/thmb/i595ecOL5Wo_Ons6aB8lINse80E=/2880x1921/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2186482541-b5eda0fcf8804c42a77ef0d338260a7e.jpg","is_english":true,"pubTime":"2024-12-20 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492647445","market":"us","top_or_hot":-1,"title":"Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug","media":"Investopedia","content":"<div>\n<p>Key Takeaways\nNovo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial.The new drug, CagriSema, led patients to lose 22.7% of their ...</p>\n\n<a href=\"https://www.investopedia.com/novo-nordisk-sinks-on-disappointing-trial-results-for-next-gen-weight-loss-drug-8764801\">Source Link</a>\n\n</div>\n","source":"investopedia_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 21:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investopedia.com/novo-nordisk-sinks-on-disappointing-trial-results-for-next-gen-weight-loss-drug-8764801><strong>Investopedia</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Takeaways\nNovo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial.The new drug, CagriSema, led patients to lose 22.7% of their ...</p>\n\n<a href=\"https://www.investopedia.com/novo-nordisk-sinks-on-disappointing-trial-results-for-next-gen-weight-loss-drug-8764801\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0820561909.HKD","symbol_name":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","start_time":0,"source_url":"https://www.investopedia.com/novo-nordisk-sinks-on-disappointing-trial-results-for-next-gen-weight-loss-drug-8764801","article_id":"2492647445","we_media_id":null,"thumbnails":["https://www.investopedia.com/thmb/i595ecOL5Wo_Ons6aB8lINse80E=/2880x1921/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2186482541-b5eda0fcf8804c42a77ef0d338260a7e.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492647445","pubTimestamp":1734699823,"columns":[],"sourceInfo":{"source_id":"investopedia_highlight","name":"Investopedia"},"weMediaInfo":null,"summary":"Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial.The new drug, CagriSema, led patients to lose 22.7% of their body weight on average, below the company's reported goal of 25%, per Bloomberg.The drug combines semaglutide, the active ingredient in Ozempic and Wegovy, with another ingredient meant to reduce hunger and make patients feel full for longer.Novo Nordisk's  U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozempic and Wegovy.The Danish drugmaker's stock was down 17% Friday morning after it had already been trending lower since September, when sales slowed slightly and concerns started to grow about the increasing competition in the weight loss drug market.Novo Nordisk said Friday that in the study of just over 3,400 patients, its new injectable weight loss drug CagriSemamet its prima","collect":0,"end_time":0,"defaultTopTitle":"investopedia.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","NVO":"诺和诺德","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LLY":"礼来","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","GEN":"GEN DIGITAL INC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","BK7104":"黄金","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","NVO.AU":"NOVO RESOURCES CORP-CDI","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999014906.USD":"大华全球优质成长基金Acc USD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4516":"特朗普概念","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","BK4532":"文艺复兴科技持仓","LU0238689110.USD":"贝莱德环球动力股票基金","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD"},"translate_title":"诺和诺德因下一代减肥药试验结果令人失望而陷入困境","themeId":"4de5f7200a34a5a69d5dce1d967bfe14","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GEN":1,"NVO.AU":1,"NVO":1,"LLY":1},"content_text":"Key Takeaways\nNovo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss drug trial.The new drug, CagriSema, led patients to lose 22.7% of their body weight on average, below the company's reported goal of 25%, per Bloomberg.The drug combines semaglutide, the active ingredient in Ozempic and Wegovy, with another ingredient meant to reduce hunger and make patients feel full for longer.\n Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozempic and Wegovy.\n\n\n The Danish drugmaker's stock was down 17% Friday morning after it had already been trending lower since September, when sales slowed slightly and concerns started to grow about the increasing competition in the weight loss drug market.\n\n\n  New Drug Led to 22.7% Weight Loss  \n Novo Nordisk said Friday that in the study of just over 3,400 patients, its new injectable weight loss drug CagriSema met its primary goal, with an average weight loss of 22.7% of a patient's body weight.\n\n\n That compared to 11.8% and 16.1% of body weight lost by the patients who took doses of just one of the two drugs that make up CagriSema, cagrilintide and semaglutide — the latter of which is the active ingredient in Ozempic and Wegovy.\n\n\n The ingredients in the drug are designed to mimic chemicals released in the body after people eat, helping people feel full for longer, making it easier to reduce how much they eat.\n\n\n The 22.7% average mark fell short of Novo Nordisk's goal reported last month by Bloomberg of 25% weight loss. Novo Nordisk said about 40% of people taking CagriSema reached the 25% mark.\n\n\n Just 57% of CagriSema patients reached the highest dosage level of the drug available during the trial, compared to 82.5% and 70.2% of the cagrilintide and semaglutide patients, respectively, who took the highest dose of those drugs.\n\n\n Novo Nordisk's U.S. shares were down 19.5% in premarket trading, poised to open at their lowest point since August 2023, after entering the day roughly flat this year. Shares of weight loss rival Eli Lilly (LLY) rose 7% following the trial results.\n\nDo you have a news tip for Investopedia reporters? Please email us at\ntips@investopedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492647445"}